Mammography Rates Low in Cancer Survivors

BY MARY ANN MOON

ost young women who received chest radiation for childhood cancer are not being appropriately screened for breast cancer, despite their high risk, according to a report.

The main barrier to screening is not a lack of medical contact; rather, it is that their physicians do not advise them to undergo mammography, most likely because the clinicians are not aware of these patients' high risk, said Dr. Kevin C. Oeffinger of Memorial Sloan-Kettering Cancer Center, New York, and his associates.

Experts recommend that women who were treated with moderate- to highdose chest radiation for a pediatric malignancy initiate breast cancer surveillance starting at age 25 years, or 8 years after undergoing radiotherapy, whichever comes last. The median age of breast

cancer diagnosis in these patients is 32-35 years, and their previous exposure to radiation or anthracycline limits their treatment options.

There are an estimated 20,000-25,000 such women in the United States, and as many as 20% of female cancer survivors worldwide fall into this category.

Dr. Oeffinger and his colleagues studied breast cancer surveillance using the large, geographically diverse population

of women participating in the Childhood Cancer Survivor Study. This study follows more than 9,000 survivors who were diagnosed between 1970 and 1986.

A random sample of 551 CCSS participants now aged 25-50 years who received at least 20 Gy of chest radiation therapy as children were surveyed regarding breast cancer surveillance. Two comparison groups-561 CCSS subjects who had not undergone chest radiation and 622 siblings of CCSS subjects who had never had cancer—also were assessed.

Nearly half of the women under age 40 years who had been exposed to pediatric radiotherapy had never had a mammogram, and only 23% had undergone mammography within the preceding year. This "much lower than expected" rate was still somewhat higher than the rates in the CCSS siblings (11%) and the cancer survivors who had not undergone chest radiotherapy (15%).

Women in this age group who said their physicians had recommended mammography were three times more likely to undergo screening than were those who said their physicians had not. However, only one-third of these highrisk women said that their physicians had recommended mammography.



Many childhood cancer survivors are not being screened for breast cancer.

The two most commonly reported barriers to screening in this age group were "doctor didn't order it" (31%) and "I'm too young" (30%).

Women aged 40-50 years who had been exposed to radiotherapy fared slightly better, but still only 53% engaged in regular breast cancer screening. In this age group, the most commonly reported barriers to screening were "put it off," "didn't get around to it," "too expensive," or "no insurance."

In contrast, nearly 90% of the study participants reported having a recent Pap smear, so medical access and knowledge of general women's health issues were not lacking. Instead, "one of the primary barriers is likely a lack of clinician familiarity with childhood cancer survivors and their risk of breast cancer,' Dr. Oeffinger and his colleagues said (JAMA 2009;301:404-14).

Thanks!



For making us America's #1 Brand.

We can't thank doctors enough for recommending Osteo Bi-Flex® to their patients. Now, doctors can feel even better about recommending Osteo Bi-Flex® because it is the only joint care brand with Joint Shield™ Joint Shield™ is specially formulated with 5-LOXIN® to help patients with their joint flare-ups* Plus, Osteo Bi-Flex® has the naturally sourced Glucosamine and Chondroitin that help lubricate and cushion joints* Osteo Bi-Flex® is clinically tested and manufactured under the strictest standards for product purity and potency. It's no wonder doctors recommend Osteo Bi-Flex® to their patients more than any other brand of Glucosamine/Chondroitin or Glucosamine supplements?

Free Sample Kit."

Call 1-888-848-2435 or visit www.osteobiflex.com to receive your free patient samples of Osteo Bi-Flex® and for a free copy of "The Science Behind Osteo Bi-Flex®"

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.